Tyra Biosciences, Inc. Board of Directors

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Dr. Todd Harris Ph.D.

Dr. Todd Harris Ph.D.

Co-Founder, President, CEO, Secretary, Treasurer & Director

Dr. Ronald V. Swanson Ph.D.

Dr. Ronald V. Swanson Ph.D.

Chief Scientific Officer

Ms. Sarah Honig

Ms. Sarah Honig

Vice President of Corporate Development & Strategy

Mr. Alan Fuhrman CPA

Mr. Alan Fuhrman CPA

Chief Financial Officer

Liz Pagano

Liz Pagano

Senior Vice President of Human Resources

Dr. Robert L. Hudkins Ph.D.

Dr. Robert L. Hudkins Ph.D.

Chief Technology Officer

Dr. Douglas Warner M.D.

Dr. Douglas Warner M.D.

Chief Medical Officer

Dr. Piyush R. Patel Ph.D.

Dr. Piyush R. Patel Ph.D.

Chief Development Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.